Peter Heeckt
Director/Board Member at Speratum Biopharma, Inc.
Profile
Peter Heeckt is currently a Director at Speratum Biopharma, Inc. He was previously a Chief Medical Officer at Smith + Nephew, Inc. and Bioventus LLC.
He obtained a doctorate degree from Ludwig-Maximilians-Universität München.
Peter Heeckt active positions
Companies | Position | Start |
---|---|---|
Speratum Biopharma, Inc.
Speratum Biopharma, Inc. BiotechnologyHealth Technology Speratum Biopharma, Inc. is a pre-clinical stage biotechnology company based in Dover, DE. Speratum is focused on the research and development of targeted molecular therapeutics for the treatment of cancer. The company's primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of mir-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids. Speratum's platforms for drug delivery and oligonucleotide administration have broad application potential, and have been out-licensed for multiple therapeutic and research modalities. The company was founded by Christian Marín-Müller, who has been the CEO since incorporation. | Director/Board Member | - |
Former positions of Peter Heeckt
Companies | Position | End |
---|---|---|
Bioventus LLC
Bioventus LLC Medical SpecialtiesHealth Technology Bioventus LLC is a holding company, which manufactures medical equipment. It develops bone healing devices and distributes osteoarthritis injection therapies. Its products include ultrasound bone healing device, joint therapies, and osteoarthritis injection therapies. The company was founded in 2012 and is headquartered in Durham, NC. | Chief Tech/Sci/R&D Officer | 2017-12-31 |
Smith + Nephew, Inc.
Smith + Nephew, Inc. Medical SpecialtiesHealth Technology Smith & Nephew, Inc. develops and markets medical devices. Its products include television cameras and monitors, endoscopes, arthroscopes, orthopedic hand owered instruments, fiber optic illumination systems, laparoscopes, and surgical instruments. The company was founded on November 27, 1975 and is headquartered in Memphis, TN. | Chief Tech/Sci/R&D Officer | - |
Training of Peter Heeckt
Ludwig-Maximilians-Universität München | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Smith + Nephew, Inc.
Smith + Nephew, Inc. Medical SpecialtiesHealth Technology Smith & Nephew, Inc. develops and markets medical devices. Its products include television cameras and monitors, endoscopes, arthroscopes, orthopedic hand owered instruments, fiber optic illumination systems, laparoscopes, and surgical instruments. The company was founded on November 27, 1975 and is headquartered in Memphis, TN. | Health Technology |
Bioventus LLC
Bioventus LLC Medical SpecialtiesHealth Technology Bioventus LLC is a holding company, which manufactures medical equipment. It develops bone healing devices and distributes osteoarthritis injection therapies. Its products include ultrasound bone healing device, joint therapies, and osteoarthritis injection therapies. The company was founded in 2012 and is headquartered in Durham, NC. | Health Technology |
Speratum Biopharma, Inc.
Speratum Biopharma, Inc. BiotechnologyHealth Technology Speratum Biopharma, Inc. is a pre-clinical stage biotechnology company based in Dover, DE. Speratum is focused on the research and development of targeted molecular therapeutics for the treatment of cancer. The company's primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of mir-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids. Speratum's platforms for drug delivery and oligonucleotide administration have broad application potential, and have been out-licensed for multiple therapeutic and research modalities. The company was founded by Christian Marín-Müller, who has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Peter Heeckt